Get the Stockscreener App
10.54
8.10%
0.79
Personalis Inc stock is traded at $10.54, with a volume of 3.82M.
It is up +8.10% in the last 24 hours and up +56.85% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$9.75
Open:
$10
24h Volume:
3.82M
Relative Volume:
1.62
Market Cap:
$1.10B
Revenue:
$64.52M
Net Income/Loss:
$-95.55M
P/E Ratio:
-10.36
EPS:
-1.0169
Net Cash Flow:
$-84.65M
1W Performance:
+11.89%
1M Performance:
+56.85%
6M Performance:
+33.00%
1Y Performance:
+61.41%
1-Day Range:
$9.885
$10.58
1-Week Range:
$9.33
$10.63
52-Week Range:
$3.84
$12.53
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
10.54 | 1.02B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
464.61 | 171.57B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.17 | 125.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.09 | 43.08B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
127.06 | 35.11B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.44 | 35.05B | 3.77B | 449.25M | 240.68M | 7.8556 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Q1 2026 Personalis Inc Earnings Call Transcript - GuruFocus
Personalis Inc (PSNL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Personalis Inc (PSNL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Personalis Inc (PSNL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Personalis Inc (PSNL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Personalis Inc (PSNL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Personalis Inc (PSNL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PSNL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines on Weak ResultsRetail Earnings Report - newsline.com
Personalis (NASDAQ: PSNL) director receives 6,250 RSU award in Form 4/A update - Stock Titan
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Lightspeed funds (NASDAQ: PSNL) report 5.8% Personalis stake after in-kind distributions - Stock Titan
Personalis Inc. (PSNL) Q1 2026 Earnings: Loss Wider Than Expected, Stock DipsPost-Announcement Reaction - newsline.com
Personalis blood collection kits receive EU regulatory approval - Investing.com UK
Personalis (PSNL) Receives CE Mark Approval for Blood Collection Kits - GuruFocus
Personalis Gains EU Approval for Blood Collection Kits Used in Genomic Testing - Moomoo
Personalis blood collection kits receive EU regulatory approval By Investing.com - Investing.com Nigeria
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire
Personalis, Inc. Hits Day Low of $10.39 Amid Price Pressure - MarketsMojo
Personalis, Inc. Hits New 52-Week High of $11.84, Up 763.64% - MarketsMojo
Personalis CFO Aaron Tachibana sells $480,400 in company stock - Investing.com UK
Personalis CFO Aaron Tachibana sells $480,400 in company stock By Investing.com - Investing.com Australia
Personalis (NASDAQ: PSNL) CFO sells 40,000 shares under 10b5-1 plan - Stock Titan
Personalis Inc. (PSNL) Q1 2026 Earnings: EPS Misses Estimates Amid Revenue Reporting GapsNegative Surprise Momentum - newsline.com
Aaron L. Tachibana (PSNL) exercises 40,000 options; prior 38,799 10b5-1 sale - Stock Titan
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? - The Globe and Mail
Personalis Inc. (PSNL) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesEPS Estimate Trend - newsline.com
Personalis Data Highlights Early Cancer Recurrence Detection - Clinical Lab Products
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - BioSpace
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Personalis Insider Sold Shares Worth $449,292, According to a Recent SEC Filing - marketscreener.com
Personalis stock hits 52-week high at $11.51 By Investing.com - Investing.com Australia
Personalis CEO Christopher M. Hall sells $1.1m in stock By Investing.com - Investing.com India
Personalis CEO Christopher M. Hall sells $1.1m in stock - Investing.com
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock By Investing.com - Investing.com Australia
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock - Investing.com
Personalis (NASDAQ: PSNL) CEO sells 100K shares after exercising options - Stock Titan
Personalis (PSNL) CFO sells shares via pre-set Rule 10b5-1 plan - Stock Titan
Personalis (PSNL) Is Up 34.5% After CMS Expands NeXT Personal MRD Test Medicare Coverage - simplywall.st
[144] Personalis, Inc. SEC Filing - Stock Titan
Personalis, Inc. Hits Day High with 15.7% Surge in Stock Price - MarketsMojo
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):